Diana Romero: How timely of us at Nature Reviews Oncology to publish a piece on financial toxicity the day after ESMO 23 finishes

Diana Romero shared a post by Nature Reviews Oncology on X/Twitter:

“How timely of us at Nature Reviews Oncology to publish a piece on financial toxicity the day after ESMO 23 finishes. There is only so much we can plan in terms of Production timelines and thus, this was not planned, but it makes for a sobering situation.”

Quoting Nature Reviews Oncology’s post:

“In a News and Views now published online, Christopher Su and Veena Shankaran discuss the PRO-TECT trial of digital symptom assessment-based screening for financial toxicity.”

Source: Diana Romero/Twitter and Nature Reviews Oncology/Twitter.

Diana Romero is the Chief Editor of Nature Reviews Clinical Oncology. Diana obtained her PhD in Biochemistry from the Universidad Autonoma de Madrid (Spain), where she studied the role of TGF-β in cancer progression in Miguel Quintanilla’s group. She joined Calvin Vary’s laboratory at Maine Medical Center Research Institute (US) for her first postdoctoral project, which was related to TGF-β receptor signalling and prostate cancer. In 2010 she moved to Robert Kypta’s group at Imperial College London (UK) as a postdoc. While maintaining her interest in prostate cancer, her project focused on Dickkopf-3 signalling. Diana joined the Nature Reviews Clinical Oncology team in July 2015, and became Chief Editor of the journal in September 2017.